2025年二季报逐步披露,多位明星基金经理最新调仓情况浮出水面。今年以来,创新药板块表现持续亮眼,不仅众多医药基金经理纷纷投向创新药,多位有资深投资经验的市场老将们也在二季度增配了医药板块,如睿远基金傅鹏博、永 赢基金高楠等人。展望后市,多位基金经理认为创新药的行情有望延续。不过需要注意的是,创新药虽然是一个具有长期逻辑的板块,但前期已经累积了一定的涨幅,未来不可避免会出现调整与波动。傅鹏博:增配...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.